Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: A systematic review and updated meta-analysis

DARU, Journal of Pharmaceutical Sciences

Volumn 20, Issue 1, 2012, Pages

  Nikfar, Shekoufeh ^a,b   Rahimi, Roja ^c   Hendoiee, Narjes ^d   Abdollahi, Mohammad ^c  

^a MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Evidence based medicine; Malformation; Meta analysis; Pregnancy outcome; Selective serotonin reuptake inhibitors (SSRIs); Systematic review

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

CARDIOVASCULAR MALFORMATION; CARDIOVASCULAR RISK; CONGENITAL MALFORMATION; DRUG SAFETY; FIRST TRIMESTER PREGNANCY; HIGH RISK PREGNANCY; HUMAN; META ANALYSIS; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PSYCHOPHARMACOTHERAPY; PUERPERAL DEPRESSION; REVIEW; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; TERATOGENICITY;

EID: 84872103539     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/2008-2231-20-75     Document Type: Review

References (38)

1. Prevalence and associated factors of depressive and anxiety symptoms during pregnancy: a population based study in rural Bangladesh. Nasreen HE, Kabir ZN, Forsell Y, Edhborg M, BMC Women's Health 2011 11 22 10.1186/1472-6874-11-22 23254679
2. Depressed mood in pregnancy: prevalence and correlates in two Cape Town peri-urban settlements. Hartley M, Tomlinson M, Greco E, Comulada WS, Stewart J, le Roux I, Mbewu N, Rotheram-Borus MJ, Reprod Health 2011 8 9 10.1186/1742-4755-8-9 21535876
3. New insights into perinatal depression: pathogenesis and treatment during pregnancy and postpartum. Meltzer-Brody S, Dialogues Clin Neurosci 2011 13 89 100 21485749
4. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ, Arch Gen Psychiatry 2010 67 1012 1024 10.1001/archgenpsychiatry.2010.111 20921117
5. Association between antenatal depression and low birth weight in a developing country. Rahman A, Bunn J, Lovel H, Creed F, Acta Psychiatr Scand 2007 115 481 486 10.1111/j.1600-0447.2006.00950.x 17498160
6. Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials. Rahimi R, Nikfar S, Abdollahi M, Reprod Toxicol 2006 22 571 575 10.1016/j.reprotox.2006.03.019 16720091
7. Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian mother and child cohort study. Nordeng H, van Gelder MM, Spigset O, Koren G, Einarson A, Eberhard-Gran M, J Clin Psychopharmacol 2012 32 186 194 10.1097/JCP.0b013e3182490eaf 22367660
8. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Malm H, Artama M, Gissler M, Ritvanen A, Obstet Gynecol 2011 118 111 120 10.1097/AOG.0b013e318220edcc 21646927
9. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Colvin L, Slack-Smith L, Stanley FJ, Bower C, Birth Defects Res A Clin Mol Teratol 2011 91 142 152 10.1002/bdra.20773 21381184
10. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Kornum JB, Nielsen RB, Pedersen L, Mortensen PB, Nørgaard M, Clin Epidemiol 2010 2 29 36 20865100
11. Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur. Merlob P, Birk E, Sirota L, Linder N, Berant M, Stahl B, Klinger G, Birth Defects Res A Clin Mol Teratol 2009 85 837 841 10.1002/bdra.20615 19691085
12. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Wichman CL, Moore KM, Lang TR, St Sauver JL, Jr Heise RH, Watson WJ, Mayo Clin Proc 2009 84 23 27 10.4065/84.1.23 19121250
13. Counseling pregnant women treated with paroxetine: concern about cardiac malformations. Einarson A, Koren G, Can Fam Physician 2006 52 593 594 16739830
14. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Diav-Citrin O, Shechtman S, Weinbaum D, Wajnberg R, Avgil M, Di Gianantonio E, Clementi M, Weber-Schoendorfer C, Schaefer C, Ornoy A, Br J Clin Pharmacol 2008 66 695 705 18754846
15. Hypothalamic-pituitary-adrenal (HPA) axis function in 3-month old infants with prenatal selective serotonin reuptake inhibitor (SSRI) antidepressant exposure. Oberlander TF, Grunau R, Mayes L, Riggs W, Rurak D, Papsdorf M, Misri S, Weinberg J, Early Hum Dev 2008 84 689 697 10.1016/j.earlhumdev.2008.06.008 18639992
16. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Einarson A, Pistelli A, De Santis M, Malm H, Paulus WD, Panchaud A, Kennedy D, Einarson TR, Koren G, Am J Psychiatry 2008 165 749 752 10.1176/appi.ajp.2007.07060879 18381907
17. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Källén BA, Otterblad Olausson P, Birth Defects Res A Clin Mol Teratol 2007 79 301 308 10.1002/bdra.20327 17216624
18. The use of selective serotonin reuptake inhibitors in pregnancy. Wen SW, Walker M, J Obstet Gynaecol Can 2004 26 819 822 15361279
19. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Wogelius P, Nørgaard M, Gislum M, Pedersen L, Munk E, Mortensen PB, Lipworth L, Sørensen HT, Epidemiology 2006 17 701 704 10.1097/01.ede.0000239581.76793.ae 17028507
20. Paroxetine and congenital malformations: A prospective comparative study. Vial T, Cournot MP, Bernard N, Carlier P, Jonville-Bera P, Jean-Pastor MJ, Bajhoux C, Robert E, Elefant E, Descotes J, Drug Saf 2006 29 911 1010
21. Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Sivojelezova A, Shuhaiber S, Sarkissian L, Einarson A, Koren G, Am J Obstet Gynecol 2005 193 2004 2009 10.1016/j.ajog.2005.05.012 16325604
22. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Malm H, Klaukka T, Neuvonen PJ, Obstet Gynecol 2005 106 1289 1296 10.1097/01.AOG.0000187302.61812.53 16319254
23. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. Casper RC, Fleisher BE, Lee-Ancajas JC, Gilles A, Gaylor E, DeBattista A, Hoyme HE, J Pediatr 2003 142 4 402 408 10.1067/mpd.2003.139 12712058
24. Perinatal outcome following third trimester exposure to paroxetine. Costei AM, Kozer E, Ho T, Ito S, Koren G, Arch Pediatr Adolesc Med 2002 156 1129 1132 10.1001/archpedi.156.11.1129 12413342
25. Pregnancy outcome after gestational exposure to paroxetine: a prospective controlled study cohort. Diav-Citrin O, Shechtman S, Weinbaum D, Teratology 2002 65 298
26. Outcomes of prenatal antidepressant exposure. Simon GE, Cunningham ML, Davis RL, Am J Psychiatry 2002 159 2055 2061 10.1176/appi.ajp.159.12.2055 12450956
27. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Einarson A, Fatoye B, Sarkar M, Lavigne SV, Brochu J, Chambers C, Mastroiacovo P, Addis A, Matsui D, Schuler L, Einarson TR, Koren G, Am J Psychiatry 2001 158 1728 1730 10.1176/appi.ajp.158. 10.1728 11579012
28. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M, Ormond K, Matsui D, Stein-Schechman AK, Cook L, Brochu J, Rieder M, Koren G, JAMA 1998 279 609 610 10.1001/jama.279.8.609 9486756
29. Neurodevelopment of children exposed in utero to antidepressant drugs. Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Theis JG, Kulin N, Koren G, N Engl J Med 1997 336 258 262 10.1056/NEJM199701233360404 8995088
30. Birth outcomes in pregnant women taking fluoxetine. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL, N Engl J Med 1996 335 1010 1015 10.1056/NEJM199610033351402 8793924
31. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S, Donnenfeld A, McCormack M, Leen-Mitchell M, Woodland C, et al. JAMA 1993 269 2246 2248 10.1001/jama.1993.03500170076037 8474204
32. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH, BMJ 2009 339 3569 10.1136/bmj.b3569 19776103
33. Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors. Bar-Oz B, Einarson T, Einarson A, Boskovic R, O'Brien L, Malm H, Bérard A, Koren G, Clin Ther 2007 29 918 926 10.1016/j.clinthera.2007.05.003 17697910
34. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Wurst KE, Poole C, Ephross SA, Olshan AF, Birth Defects Res A Clin Mol Teratol 2010 88 159 170 10.1002/bdra.20627 19739149
35. Interventions for preventing osteoporosis in women on heparin therapy during pregnancy. Abdollahi M, Nikfar S, Hosseini-Tabatabaei A, Rezaie A, Cochrane Database Syst Rev 2010 6 D008547
36. A meta-analysis on the efficacy and safety of combined vitamin C and E supplementation in preeclamptic women. Rahimi R, Nikfar S, Rezaie A, Abdollahi M, Hypertens Pregnancy 2009 28 4 417 34 10.3109/10641950802629667 19843004
37. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Rahimi R, Nikfar S, Rezaie A, Abdollahi M, Reprod Toxicol 2008 25 271 275 10.1016/j.reprotox.2007. 11.010 18242053
38. Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. Nikfar S, Abdollahi M, Moretti ME, Magee LA, Koren G, Dig Dis Sci 2002 47 7 1526 1529 10.1023/A:1015863018105 12141812